The Institute of Cancer Research

The Institute of Cancer Research The ICR is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years.

Our mission is to make the discoveries that defeat cancer. The Institute of Cancer Research is making the discoveries that defeat cancer. In addition to being a leading cancer research organisation, we are also a postgraduate college (a member of the University of London), as well as a charity. To make a donation to support our work please visit icr.ac.uk/donate

12/08/2026

Terry Fox 2026! We’re gearing up for this year’s events and we are so excited 🏃‍♀️🏃‍♂️❤️

It’s been 46 years since Canadian legend Terry Fox set out on his Marathon of Hope. Starting on Canada’s easternmost coast after cancer treatment led to the amputation of his right leg, Terry ran 26 miles a day on a prosthetic leg to raise money for cancer research.

We’re honoured that the funds raised through the Terry Fox Run will support our life-saving research, led by our dedicated scientists and researchers.

This year, we’re excited to welcome Sussex as a Terry Fox Run location for the very first time, joining our events throughout September in Battersea Park, Glasgow, Hampshire, Edinburgh and Wrexham.

Whether you choose to run, walk, cycle or simply come along and cheer others on, we’d love to have you with us.

Sign up today and help change lives by heading to the link in our bio 🔗

12/08/2026

Terry Fox 2026! We're gearing up for this year's events and we are so excited! Terry Fox Run UK for The Institute of Cancer Research

❤️ It's been 46 years since Canadian legend Terry Fox set out on his Marathon of Hope. Starting on Canada's easternmost coast after cancer treatment led to the amputation of his right leg, Terry ran 26 miles a day on a prosthetic leg to raise money for cancer research.

We're honoured that the funds raised through the Terry Fox Run will support our life-saving research, led by our dedicated scientists and researchers.

📍This year, we're especially excited to welcome Sussex as a Terry Fox Run location for the very first time, joining our events throughout September in Battersea Park, Glasgow, Hampshire, Edinburgh and Wrexham.

Whether you choose to run, walk, cycle or simply come along and cheer others on, we'd love to have you with us.

Head to the link in the comments to sign up today and help change lives. ⤵

🚨NEWS🚨The ICR welcomes the news that camizestrant, a powerful new drug for advanced breast cancer that can be used to tr...
10/08/2026

🚨NEWS🚨The ICR welcomes the news that camizestrant, a powerful new drug for advanced breast cancer that can be used to treat emerging tumours, has been approved by the medicines regulator, the MHRA.

The drug has been approved to be used, in combination with a CDK4/6 inhibitor, for the treatment of ER-positive, HER2-negative, locally advanced or metastatic breast cancer.

The approval is based on results from the SERENA-6 Phase III trial, co-led by the ICR’s Professor Nick Turner. The trial found that patients who were given the drug combination cut the chances of their cancer getting worse by over half, allowing them to stay on first-line therapy for longer.

07/08/2026

We were delighted to welcome Caroline to our Sutton site for a lab tour with Professor Trevor Graham and his team.

Caroline's son, Bradley, was diagnosed with advanced bowel cancer at just 22 years old and died 18 months later.

During the visit, Professor Graham, Professor of Genomics and Evolution, shared more about our bowel cancer research, including the groundbreaking Boomers Project.

Using detailed molecular analysis of tumour samples from the 1960s, this study investigates how bowel cancer has changed over time and seeks to uncover what may be driving the increase in cases today.

Caroline shared her story as part of our bowel cancer appeal, highlighting how continued support can help us accelerate our research and bring hope to people affected by bowel cancer.

❤ Read Caroline’s story and learn how you can support our life-saving research
https://www.icr.ac.uk/research-and-discoveries/cancer-blogs/detail/science-talk/research-won-t-bring-bradley-back--but-it-might-help-others----caroline's-story?fbclid=IwY2xjawThjhxleHRuA2FlbQIxMABicmlkETFJQkREVkx3SmxBYmptSk14c3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHqIiQAuvzwLmBFrpLnp2Bmge0m1XptyTgZPZ9dCp3XmbYZKv764L-xvND6a3_aem_b2clLF-LDgPq6UniTO0XZQ

06/08/2026

🚨 We are looking for people from Black African, Black African-Caribbean, and Asian communities to help transform the future of prostate cancer screening.

We are teaming up with The Royal Marsden NHS Foundation Trust and Imperial College London for the i4i PRODICT® study, funded by the NIHR (National Institute for Health and Care Research) Invention for Innovation Programme.

The study will help researchers estimate a person’s risk of getting prostate cancer and understand how this risk varies across different ethnic backgrounds.

Participants found to be at higher risk will be invited for annual prostate cancer screening for three years. If treatment is needed, it will be available at The Royal Marsden or your local cancer centre.

With your help, we can develop faster and kinder prostate cancer screenings for everyone.

Learn more about the study and how you can take part ⤵️
https://www.icr.ac.uk/research-and-discoveries/icr-divisions/genetics-and-epidemiology/oncogenetics/prodict-study

NEW research finds that NICE (National Institute for Health and Care Excellence) referral criteria miss up to 95% of wom...
04/08/2026

NEW research finds that NICE (National Institute for Health and Care Excellence) referral criteria miss up to 95% of women under 50 who go on to develop within 10 years.

Researchers at the ICR and University of Cambridge compared a comprehensive risk assessment tool to the current NICE criteria.

Identifying women at higher risk can allow for additional screening or preventive treatment.

The research, published in the British Journal of Cancer, found that the new method could identify 8 times as many women under 50 who developed breast cancer as the NICE criteria.

The NICE criteria is based on family history, while the comprehensive risk assessment tool combines factors such as family history, lifestyle, reproductive history and genetic information.

ICR Professor Montserrat Garcia-Closas said: “There will be a balance to strike: the NICE criteria are much easier to implement, but miss a large proportion of women at elevated risk. But a full risk assessment including genetic testing will place a heavy burden on resources.

“Ultimately, it will be a trade-off between the practical, resource, and cost implications of data collection and risk assessment, and the potential benefits and harms associated with accurate and inaccurate classification of women.”

Breast Cancer Now



image: MRI of breast, credit National Cancer Institute

04/08/2026

Too many younger women at risk of breast cancer are being missed.

Scientists at University of Cambridge and The Institute of Cancer Research, London analysed data from the Breast Cancer Now Generations Study and found that current NICE referral criteria in the UK could miss up to 95% of women under 50 who go on to develop breast cancer within 10 years.

Using BOADICEA – a comprehensive risk assessment tool – they identified 8 times as many women in this age group who developed breast cancer.

Finding new ways to identify women at increased risk could help to prevent some breast cancers or detect them earlier, when treatment is more likely to be successful.

It’s research like this that show why long-term projects like our Generations Study is so important.

Today is World Head and Neck Cancer Day🩺 Head and neck cancer can be difficult to treat once it returns or spreads. That...
27/07/2026

Today is World Head and Neck Cancer Day🩺

Head and neck cancer can be difficult to treat once it returns or spreads. That's why our researchers are working to develop new options for patients.

Led in the UK by ICR's Professor Kevin Harrington and The Royal Marsden NHS Foundation Trust, the OrigAMI-5 trial is investigating whether the targeted therapy amivantamab could help people whose cancer has stopped responding to standard treatments.

Promising results from the OrigAMI-4 trial showed tumours shrinking in more than four in 10 patients. The OrigAMI-5 trial is now underway, building on these findings and helping researchers learn more about how this treatment could benefit patients in the future.

One patient, Carl Walsh, experienced a complete response to treatment and has spoken about the impact the trial has had on his life.

Learn more here⬇
https://www.icr.ac.uk/about-us/icr-news/detail/immunotherapy-injection-shrinks-tumours-in-patients-with-head-and-neck-cancer

We’re delighted to have received a South London Partnership Careers Hub Employer Recognition Award 2026, celebrating our...
22/07/2026

We’re delighted to have received a South London Partnership Careers Hub Employer Recognition Award 2026, celebrating our commitment to inspiring future talent in health, care and life sciences.

Working with the Careers Hub and local schools, we have welcomed young people into our research environment and given them first-hand insight into cancer research and the wide range of careers available across science and the life sciences sector.

This recognition would not have been possible without the many people who contributed. Thank you to our Public Engagement Manager for developing and coordinating the programme, to the colleagues and research volunteers who generously shared their time and knowledge, and to our Careers Hub partners, teachers and participating students.

We’re proud of what we have achieved together and look forward to opening our doors to even more young people in the future.

DREAM TEAM ❤️Last week, George Southgate and 27 incredible cyclists completed their remarkable 1,000km ride from Berlin...
18/07/2026

DREAM TEAM ❤️
Last week, George Southgate and 27 incredible cyclists completed their remarkable 1,000km ride from Berlin to London!

A smashing £165,000 has already been raised, with donations still coming in!

We are blown away by this incredible support for our life-saving research.

A huge thank you from everyone at the ICR 🌟

Address

London

Opening Hours

Monday 9am - 5:30pm
Tuesday 9am - 5:30pm
Wednesday 9am - 5:30pm
Thursday 9am - 5:30pm
Friday 9am - 5:30pm

Telephone

+442073528133

Website

Alerts

Be the first to know and let us send you an email when The Institute of Cancer Research posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organisation

Send a message to The Institute of Cancer Research:

Shortcuts

Featured

Share

Category